Transition of Anti-pertussis Antibodies and the Safety of Japanese Diphteria-acellular Pertussis-Tetanus Vaccine administered in reduced doses among Adults

Transition of Anti-pertussis Antibodies and the Safety of Japanese Diphteria-acellular Pertussis-Tetanus Vaccine administered in reduced doses among Adults - Effect and the Safety of DTP vaccine administered in reduced doses among Adults

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010779

Enrollment

200

Registered

2013-06-06

Start date

2013-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pertussis

Interventions

A term is four weeks Amout of vaccination is 0.2mL A number of times is one time

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Docters, Nurses, Nursery nurse

Exclusion criteria

Exclusion criteria: The person who is infected a malignancy

Design outcomes

Primary

Measure	Time frame
increased anti-pertussis antibodies titer after vaccination	—

Secondary

Measure	Time frame
relative frequency of side effects after vaccination	—

Countries

Japan

Contacts

Public ContactMio Kohno

National Hospital Organization Saitama National Hospital Department of Pediatrics

048-462-1101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026